Clinical Trial

Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasis

Withdrawn
View on ClinicalTrials.gov →
Why the trial stopped
Sponsor decision
Summary
The primary and secondary objectives are to respectively monitor the safety and effectiveness of Spesolimab IV in Korean patients with flares with generalized pustular psoriasis (GPP) in a routine medical practice.
Protocol Amendment History 3 changes
critical Trial status changed: Not Yet Recruiting → Withdrawn 2026-04-05
notable Enrollment reduced: 21 -> 0 participants 2026-04-05
critical Trial status changed: Not Yet Recruiting → Withdrawn 2026-04-01
Trial Details
NCT Number NCT06886009
Lead Sponsor Boehringer Ingelheim
Conditions Generalized Pustular Psoriasis
Start Date 2026-03-31
Primary Completion 2029-06-08 (estimated)
Study Completion 2029-06-08 (estimated)
Updated on ClinicalTrials.gov 2026-03-31